Master ADC Manufacturing Compliance with Wisdom's Expert Training
Training Schedule (12th & 13th December, 2024)
(12th December, 2024)
14:00 - 18:15 PM UK time
9:00 AM - 1:15 PM US EST time
(13th December, 2024)
14:00 - 18:15 PM UK time
9:00 AM - 1:15 PM US EST time
Online
Join visionary speakers from leading organisations for crucial insights and expert opinions.
Dr. Len Pattenden, Managing Director, CMC Biopharma Ltd
Training Schedule (12th & 13th December, 2024)
14:00 - 18:15 PM UK time
9:00 AM - 1:15 PM US EST time
The manufacturing of Antibody-Drug Conjugates (ADCs) is intrinsically complex and a strong chemistry, manufacturing and control (CMC) strategy is vital due to the complex nature of these therapeutics and history of failures at both early and late stages. This training encompasses a comprehensive understanding of the primary technical and regulatory (FDA and EMA) challenges; focusing on the specific requirements for ADCs, which combine the targeting capabilities of antibodies with the cell-killing or effector capabilities of payload drugs. The overall operational excellence and Quality approach is highlighted as well as the critical points for control to ensure the consistency, purity and stability of ADCs, given their high potency and specific targeting mechanisms. Training also covers good manufacturing practices (GMP) procedures - especially tech transfer, documentation and facility controls. The latter being crucial for minimizing cross-contamination risks. This training combines theoretical knowledge with workshopping for deeper understanding to prepare professionals for the unique challenges in ADC manufacturing
Dr. Len Pattenden, Managing Director, CMC Biopharma Ltd
Len has over 30 years of experience in both industry and academia. Len has been a company founder, COO and GMP site head/license holder, overseeing biopharma development and manufacture as well as outsourced CDMO activities. Len has undertaken development and manufacturing of 18 new biological entities, including first-in-man/first-in-class cell and gene therapies, viral vectors, biologics, and monoclonal antibodies. Len’s regulatory and licensing experience covers the MHRA, EMA and FDA. Len works as a CMC consultant for small and large pharmaceutical companies. He is a member of a Regulatory working group, the ISPE and BIA
This training is essential for professionals from leading pharma manufacturing companies, including:
Quality
Quality assurance
Quality Control
CMC Managers/ Heads
Compliance
Regulatory Affairs
QA/QC Managers
Analytical Scientists
Development Scientists
Manufacturing
Process Development
Upstream/Downstream
R&D Scientists
Operations
& VC/investors in Biologics
The participants will acquire knowledge through interactive sessions that are structured like lectures, allocating ample time for various activities, Q&A sessions, and discussions. Additionally, the training emphasises practical learning, incorporating case studies, breakout sessions, interactive polls, and examples from real-case scenarios.
Training Schedule (12th & 13th December, 2024)
14:00 - 18:15 PM UK time
Additional Features:
DAY 1 | 12 DECEMBER, 2024 (UK Time)
Title: Unveiling the Complexity: Introduction to ADCs and Their Mechanism of Action
Title: Navigating Complexity: GMP Manufacturing of ADCs - Steps and Challenges
Join visionary speakers from leading organisations for crucial insights and expert opinions.